The primary purpose of this study is to evaluate whether treatment with oral anticoagulation or oral anticoagulation and aspirin is better than aspirin alone in cardiovascular outcomes and saphenous graft patency in patients submitted to coronary artery bypass graft.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation
Centro Hospitalar e Universitário de Coimbra
Coimbra, Portugal
MACE
Time from randomization to the first occurrence of either myocardial infarction, stroke, or cardiovascular death
Time frame: 5 years
Graft Patency
Time from randomization to the first occurence of saphenous graft oclusion
Time frame: 5 years
Major Bleeding
Time from randomization to the first occurrence of major bleeding (modified International Society on Thrombosis and Haemostasis)
Time frame: 5 years
MACE, cardiovascular death
Time from randomization to first occurrence of either coronary heart disease death, myocardial infarction, ischemic stroke, acute limb ischemia
Time frame: 5 years
All-cause mortality
Time from randomization to first occurrence of all-cause mortality
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.